Table 1

Demographic characteristics of the study population according to gender

VariablesMale (n=174)Female (n=158)p Value
Age, years (mean±SD)32.8 (7.8)34.9 (9.3)0.037
BMI, kg/m2 (mean±SD)24.2 (3.7)24.0 (4.6)0.133
Disease duration, years (mean±SD)1.6 (1.1)1.7 (1.0)0.294
Inflammatory bowel disease (n, %)9 (5.3%)11 (7.1%)0.499
Tobacco use (n, %)66 (38.4%)48 (30.6%)0.137
Alcohol excess (n, %)39 (22.8%)7 (4.5%)<0.0001
HLA-B27 (n, %)116 (67.4%)89 (56.3%)0.038
BAS-G, last week (mean±SD)4.4 (2.5)5.3 (2.5)0.002
ASAS criteria (n, %)132 (75.9%)105 (66.5%)0.058
BASDAI (mean±SD)3.8 (1.9)4.8 (2.0)<0.0001
BASFI (mean±SD)2.4 (2.0)3.4 (2.5)0.0002
BASMI (mean±SD)1.9 (1.1)2.1 (1.0)0.115
CRP, mg/ml (mean±SD)11.6 (17.9)7.8 (10.8)0.988
CRP abnormal, ≥6 mg/dl (n, %)53 (38.7%)48 (41.4%)0.663
ASDAS–CRP (mean±SD)2.6 (1.1)2.7 (0.9)0.236
ESR, mm (mean±SD)13.3 (17.1)14.7 (15.0)0.0002
NSAID use (n, %)162 (93.1%)146 (92.4%)0.806
Radiographical sacroiliitis (n, %)60 (35.1%)34 (22.1%)0.010
  • ASAS, Assessment of Spondyloarthritis International Society; ASDAS, ankylosing spondylitis disease activity score; BASDAI, Bath ankylosing spondylitis disease activity index; BASFI, Bath ankylosing spondylitis functional index; BAS-G, Bath ankylosing spondylitis global assessment; BASMI, Bath ankylosing spondylitis metrology index; BMI, body mass index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; NSAID, non-steroidal anti-inflammatory drug.